Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 68 publications.

Selimovic N, Rundqvist B, Kjork E, Viriden J, Twiss J, McKenna SP. Adaptation and validation of the cambridge pulmonary hypertension outcome review for Sweden. Scand J Public Health. 2012 Dec;40(8):777-83. doi: 10.1177/1403494812464445

DiCesare J, Garrison L, Oster G, Sacco P. Assessing the reimbursability of new products: a structured approach. Presented at the 2012 ISPOR EUR Workshop; November 2012. Berlin, Germany.

Twiss J, Ganderton L, Jenkins S, Ben-L'amri M, Gain K, Fowler R, Gabbay E, McKenna S. Comparison of the psychometric properties of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and the SF-36 in patients with pulmonary hypertension. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A378-9.

Gnanasakthy A, Doward L, Clark M, Mordin M, DeMuro C. Concordance of pro labeling claims between the FDA and EMA. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A321.

Forsyth B, Fehnel SE, Danchenko N, François C, Brevig T. Assessing impacts of major depressive disorder on depression. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 1, 2012. Berlin, Germany.

Forsyth B, Fehnel SE, Danchenko N, Franois C, Brevig T. Assessing impacts of major depressive disorder (MDD) on cognitive function. Value Health. 2012 Nov 1;15(7):A341.

Badia X, Forsythe A, Nelson LM, Coles TM, McLeod LD, Webb SM. Improvements in health-related quality of life in acromegaly with pasireotide LAR and octreotide LAR: results from a large, randomized, double-blind phase III trial. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A505.

Twiss J, McKenna SP. Equating scores on two dermatology-specific patient-reported outcome measures. Poster presented at the 19th Annual Conference of the International Society for Quality of Life Research (ISOQOL); October 2012. Budapest, Hungary. [abstract] Qual Life Res. 2012 Oct; 21(1):94. doi: 10.1007/s11136-012-0248-x

Carson R, Nelson LM, Williams VS, Fehnel SE, Tourkodimitris S, Baird M, et al a. Psychometric evaluation of patient-reported outcome measures for assessing ibs-c symptom severity and change: results from 2 randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 1, 2012.

Carson R, Baird M, Coon C, Fehnel SE, MacDougall J, Nelson LM. Psychometric evaluation of patient-reported outcome measures assessing IBS-C symptom severity and change: results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Presented at the ISOQOL 19th Annual Conference; October 1, 2012.

Nelson LM, Williams VS, Carson R, Baird M, Coon C, Fehnel SE. Factor analyses of chronic constipation patient-reported outcome measures: results from phase 2b and phase 3 trials of linaclotide. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 1, 2012. Previously presented at the Joint International Neurogastroenterology and Motility Meeting.

Coon CD, Bokowy KL, Horblyuk R, Zisman RS, McLeod LD, Brown MT. The development and initial assessment of the strategy and leadership systems capability evaluation survey. Health Care Manag (Frederick). 2012 Oct 1;31(4):332-41.

Engelhart L, Nelson L, Lewis S, Mordin M, Demuro-Mercon C, Uddin S, McLeod L, Cole B, Farr J. Knee injury and osteoarthritis outcome score subscales for patients with articular cartilage lesions of the knee. Am J Sports Med. 2012 Oct 1;40(10):2264-72.

Forsyth B, Fehnel SE, Danchenko N, François C, Brevig T. Patient-reported cognitive symptoms and a patient-reported outcome measure of cognitive function in depression. Poster presented at the Annual European College of Neuropsychopharmacology Congress; October 1, 2012.

Cohen JT, Marino RJ, Sacco P, Terrin N. Association between the functional independence measure following spinal cord injury and long-term outcomes. Spinal Cord. 2012 Oct;50(10):728-33. doi: 10.1038/sc.2012.50

Ben-L'amri M, McKenna SP, Wilburn J, Twiss J. Assessing quality of life in new regions of the world: further development of the PsAQoL. Poster presented at the 19th Annual Conference of the International Society for Quality of Life Research (ISOQOL); October 2012. Budapest, Hungary. [abstract] Qual Life Res. 2012 Oct; 21(S1):120.

Baird M, Carson R, Coon CD, Fehnel SE, MacDougall J, Nelson LM, Williams VS. Psychometric validation of patient-reported outcome measures assessing chronic constipation symptom severity: results from phase 2b and phase 3 trials of linaclotide. Poster presented at the ISOQOL 19th Annual Conference; October 2012.

Cima K, Twiss J, Speich R, McKenna SP, Grunig E, Kahler CM, Ehlken N, Treder U, Crawford SR, Huber LC, Ulrich S. The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR). Health Qual Life Outcomes. 2012 Sep 13;10:110. doi: 10.1186/1477-7525-10-110

Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Carson RT, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing chronic constipation symptom severity and change: results from phase 2b and phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 6; 24(Suppl. s2):180.

Zografos L. Considerations for implementing surveys evaluating effectiveness: sample recruitment, ethics, and privacy. Presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 5, 2012. Barcelona.

Williams VSL, Nelson LM, Carson RT, Baird MJ, Coon CD, Fehnel SE, Johnston JM. Factor analyses of patient-reported outcome measures in Irritable Bowel Syndrome with Constipation (IBS-C): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Presented at the 2012 ACG Annual Meeting and Postgraduate Course; September 1, 2012. Previously presented at the Joint International Neurogastroenterology and Motility Meeting.

Williams VS, Nelson LM, Carson RT, Baird MJ, Coon CD, Fehnel SE. Factor analyses of patient-reported outcome measures in irritable bowel syndrome with constipation (IBS-C): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 1, 2012.

Spiegel BMR, Locke G, Kurtz CM, Williams VSL, Nelson LM, Carson RT, Currie MG, Schneier HA, Johnston JM. Clinically meaningful change benchmarks for IBS-C symptoms developed using data from two phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep; 24(s2):35.

Nelson LM, Williams VSL, Carson RT, Baird MJ, Fehnel SE, Johnston JM. Factor analyses of patient-reported outcome measures in Irritable Bowel Syndrome with Constipation (IBSC): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):106. doi: 10.1111/j.1365-2982.2012.01997.x

Nelson LM, Williams VS, Carson RT, Baird MJ, Coon CD, Fehnel SE. Factor analyses of chronic constipation patient-reported outcome measures: results from phase 2b and phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 1, 2012.

Chandran AB, Coon CD, Martin SA, McLeod LD, Coles TM, Arnold LM. Sphygmomanometry-evoked allodynia in chronic pain patients with and without fibromyalgia. Nurs Res. 2012 Sep 1;61(5):363-8.

Badia X, Roset M, Forsythe A, Coles TM, McLeod LD, Nelson LM. Clinical and patient-reported outcomes associated to pasireotide in patients with Cushing's disease. Poster presented at the 15th Annual Congress of the European Neuroendocrine Association; September 2012.

Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.

Carson RT, Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing IBS-C symptom severity and change: results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):179.

Kosa KM, Cates SC, Karns S, Godwin SL, Coppings RJ. Are older adults prepared to ensure food safety during extended power outages and other emergencies? Findings from a national survey. Educ Gerontol. 2012 Aug 14;38(11):763-75. doi: 10.1080/03601277.2011.645436

Williams V, Rousculp MD, Price M, Coles T, Therrien MA, Griffin J, Hollis K, Toback S. Elementary school-located influenza vaccine programs: key stakeholder experiences from initiation to continuation. J Sch Nurs. 2012 Aug 1;28(4):256-67.

McKenna SP, Twiss J, Crawford SR, Oprandi NC, Tammaru M, Miravitlles M. The living with chronic obstructive pulmonary disease scale was successfully adapted for use in southern european (Italian and Spanish) and eastern european (Russian) cultures. J Clin Epidemiol. 2012 Aug;65(8):906-14.

Norquist JM, Girman C, Fehnel S, Demuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res. 2012 Aug 1;21(6):1016-20.

Brown TM, Garg S, Chandran AB, McNett M, Silverman SL, Hadker N. The impact of 'best-practice' patient care in fibromyalgia on practice economics. J Eval Clin Pract. 2012 Aug 1;18(4):793-8.

Twiss J, McKenna S, Crawford S, Wilburn J, Loth K. Are transfusions for Myelodysplasia (MDS) an acceptable treatment to patients? Poster presented at the 17th Congress of European Hematology Association; June 2012. Amsterdam, the Netherlands. [abstract] Haematologica. 2012 Jul 16; 97(S1):693.

DiBenedetti DB, Lewis SA, Price MA. The role of cognitive pretesting interviews in REMS survey development. Poster presented at the Risk Evaluation and Mitigation Strategy (REMS) Assessments: Social Science Methodologies to Assess Goals Related to Knowledge Public Workshop; June 7, 2012.

Lewis S, Price M, Mordin M, Dwyer K, Heekin R, Yates P, O'Brien S, Beverland D. Assessing performance following primary total knee arthroplasty: development of the patient's knee implant performance (PKIP) measure. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. [abstract] Value Health. 2012 Jun 1; 15(4):A70.

DiFranza JR, Masaquel A, Barrett AM, Colosia AD, Mahadevia PJ. Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children. BMC Pediatr. 2012 Jun 1;12:81.

Petrillo J, Cano S, McLeod LD, Coon CD. What is the value of classical test theory, item response theory, and Rasch measurement theory in the development of patient-reported outcome instruments? Presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC.

Gnanasakthy A, Lewis SA, Clark MJ, Mordin MM, Evans E, DeMuro-Mercon CJ. The impact of primary endpoints on patient-reported outcome label claims. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012.

Nelson LM, Stull DE, Coon CD, Gnanasakthy A. Use of latent growth modeling to evaluate construct validity in longitudinal studies. Presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC.

DeMuro C, Clark M, Coon C, Evans E, Mordin M, Gnanasakthy A. Assessment of PRO labels claims granted by the FDA as compared to the EMA. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A201. doi: 10.1016/j.jval.2012.03.1085

McKenna S, Twiss J, Wilburn J, Crawford S, Loth K. Investigation of the impact of MDS from the patients' perspective. Poster presented at the 17th Congress of the European Hematology Association; June 2012. Amsterdam, The Netherlands. [abstract] Haematologica. 2012 Jun; 97(S1):357-8.

Chen S, Wu N, Boulanger L, Sacco P. Economic burden of refractory epilepsy with partial onset seizures: an assessment of direct health care resource use and costs. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A143.

Brown TM, Olanrewaju B, Deal L, Katz EC, Chiou C, Martin S, Fehnel S. Assessing pruritus among patients with atopic dermatitis: targeted literature and instrument review. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. [abstract] Value Health. 2012 Jun; 15(4):A253.

Brown TM, Siu K, Walker D, Pladevall-Vila M, Sander S, Mordin M. Development of a conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with atrial fibrillation. J Manag Care Pharm. 2012 Jun 1;18(5):351-62.

Gnanasakthy A, Sadrick A, DeMuro C, Rahul R. Promotion of patient reported outcomes (PRO) label claims based on non-primary endpoints. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A201. doi: 10.1016/j.jval.2012.03.1086

Gnanasakthy A, Lewis S, Clark M, Evans E, Mordin M, DeMuro C. Reported outcomes as primary endpoints in confirmatory clinical trials. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A200.

Spiegel BMR, Locke GR, Kurtz C, Williams VS, Nelson LM, Carson RT. Developing benchmarks for clinically meaningful change for ibs-c symptoms using data from two phase 3 trials of linaclotide. Poster presented at the 2012 Digestive Disease Week; May 2012.

DeMuro C, Clark M, Mordin M, Fehnel S, Copley-Merriman C, Gnanasakthy A. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and niologic license applications, 2006-2010. Value Health. 2012 May 1;15(3):443-8.